anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will be conducted as a controlled, randomized, two-group parallel and superiority clinical trial with a 1:1 allocation ratio. The sample will be divided into two groups: 1) capoeira training group (n = 76; GCAP) and 2) control group (n = 76; GCONT). Participants aged between 18 and 59 years, classified as irregularly active A by the international physical activity questionnaire, who are not engaged in training programs and are not former athletes, will be eligible. Smokers and patients with respiratory or cardiovascular diseases will be excluded from the sample. Anamnesis and anthropometric evaluation will initially be performed. To evaluate the physical aspects, specific tests will be applied to determine aerobic and anaerobic fitness, strength and power of lower limbs, balance, motor coordination and questionnaires will be applied to verify the psychological aspects, such as emotional intelligence, motivation and quality of life. The descriptive analysis of the outcomes will be reported. The normality of the data will be checked by visual inspection of the Q-Q plot and statistically tested by the Shapiro-Wilk test. Two-way ANOVA for repeated measures will be employed to verify the time\*group interaction. The effect size (ES) of the intervention on dependent variables will be calculated and the difference between the ES and its respective 95% confidence interval will be calculated to estimate the magnitude of the response in the intervention. The alpha adopted will be 5% and the software used for data analysis will be Statistical Packages for the Social Sciences 25.0.
OBJECTIVE: To assess the safety and effectiveness of the indocyanine green use in acute cholecystitis for identification of anatomical variants of the biliary tree; prevention and timely detection of intraoperative complications.
MATERIAL AND METHODS: The medication of indocyanine green made by OOO «Ferment» domestic manufacturer was used. The drug dose from 2.5 mg to 10 mg was applied according to studied materials (8). Time of the surgery beginning was from 2 to 6 hours after intravenous injection of aqueous solution, respectively. In addition, it has been established that the optimal drug dose is 5 mg. The surgery should be performed not earlier than 3 hours after, but no later than 6 hours. This allows to achieve the most comfortable fluorescence of the extrahepatic biliary tract. The drug concentration in the liver cells decreases by this time and increases in the biliary tract. It is not always possible to perform the operation strictly within the specified time limit considering the urgency of the surgical intervention. In this connection, the surgery was carried out not earlier than 3 hours after the drug injection, but not later than 6 hours. Endoscopic equipment with the ability to display near-infrared fluorescence was used. A laser light source with a wavelength of 820 nm in the Arthrex imaging system with 4K resolution as well as the Olympus imaging system with HD resolution were used for fluorescence excitation.
RESULTS: The implementation of intraoperative fluorescent navigation with indocyanine green contributes to the improvement of safety and effectiveness of surgical treatment through visualization of topography and identification of anatomical variants of the biliary tree; possibilities of prevention and timely detection of intraoperative complications. The use of indocyanine green allows to intraoperatively reveal atypical location and different variations of the extrahepatic biliary tract.
Oxymorphone hydrochloride tablet, USP is an opioid agonist available in 5 mg and 10 mg tablet strengths for oral administration. The chemical name for oxymorphone hydrochloride is 4, 5α-epoxy-3, 14-dihydroxy-17-methylmorphinan-6-one hydrochloride. The molecular weight is 337.80. The molecular formula is C17H19NO4.HCl and it has the following chemical structure.

Oxymorphone hydrochloride, USP is white to off white powder, which is soluble in water, sparingly soluble in alcohol and ether.

The inactive ingredients in oxymorphone hydrochloride tablets, USP include: lactose anhydrous, magnesium stearate, microcrystalline cellulose and pregelatinized starch. In addition, the 10 mg tablets contain D&C red No. 30 talc lake.

USP Dissolution Test Pending.
EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
Novel derivatives of perhydroisoindol of general formula (I) in which the radicals R are hyrdrogen atoms or together form a bond, the symbols R' are phenyl radicals which can be substituted by a halogen atom or a methyl radical in position 2 or 3, X is an oxygen atom or an NH radical, R1? is optionally substituted phenyl, or cyclohexadienyl, naphthyl, or heterocyclyl, R2? is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyloxycarbonyl, benzyloxycarbonyl, amino or acylamino, R3? is halogen or OH and R4? is H or halogen if R3? is halogen, in their isomer forms, or mixtures thereof, and possibly also their salts when they exist, and preparation thereof. The novel derivatives of the invention are particularly interesting as P substance antagonists.
Eosinophilic fasciitis is a rare sclerodermiform disease characterized by upper and lower limb edema. We present the case of a 71-year-old woman currently hospitalized for painful lower limb edema. Laboratory tests reveal moderate eosinophilia (0.8 g/L) and an inflammatory syndrome. Abdominopelvic ultrasound reveals no abnormalities. In light of the unexplained inflammatory syndrome, a 18 F-FDG PET/CT scan currently shows intense hypermetabolism of the fasciae in the lower and upper limbs. Following an MRI, a biopsy is performed, and the anatomopathology currently confirms eosinophilic fasciitis.
The invention relates to a compound medicine for treating sicca syndrome and a preparation method thereof. The medicine is characterized in that Chinese medicinal herb components with reasonable compatibility are selected. The medicine is prepared from the following effective components: ophiopogon root, dangshen, rhizoma atractylodis macrocephalae, Chinese yam, schisandra fruit, tuckahoe, radix rehmanniae, testa trionidis, dendrobe, kudzu root and licorice. The medicine is prepared from pure Chinese medicinal herb components and is free of any chemical component. The Chinese medicinal herb components are strictly screened and proportioned through the experiments, so the medicine has favorable compound effect. The medicine is prepared by a special technique, has the advantages of stable quality and no toxic or side effect on the human body, is convenient to take, and is used for treating chronic inflammation autoimmune disease-sicca syndrome which mainly infringes salivary glands and lacrimal glands.
BACKGROUND: Excessive lipid accumulation in the adipose tissue in obesity alters the endocrine and energy storage functions of adipocytes. Adipocyte lipid droplets represent key organelles coordinating lipid storage and mobilization in these cells. Recently, we identified the small GTPase, Rab34, in the lipid droplet proteome of adipocytes. Herein, we have characterized the distribution, intracellular transport, and potential contribution of this GTPase to adipocyte physiology and its regulation in obesity.
METHODS: 3T3-L1 and human primary preadipocytes were differentiated in vitro and Rab34 distribution and trafficking were analyzed using markers of cellular compartments. 3T3-L1 adipocytes were transfected with expression vectors and/or Rab34 siRNA and assessed for secretory activity, lipid accumulation and expression of proteins regulating lipid metabolism. Proteomic and protein interaction analyses were employed for the identification of the Rab34 interactome. These studies were combined with functional analysis to unveil the role played by the GTPase in adipocytes, with a focus on the actions conveyed by Rab34 interacting proteins. Finally, Rab34 regulation in response to obesity was also evaluated.
RESULTS: Our results show that Rab34 localizes at the Golgi apparatus in preadipocytes. During lipid droplet biogenesis, Rab34 translocates from the Golgi to endoplasmic reticulum-related compartments and then reaches the surface of adipocyte lipid droplets. Rab34 exerts distinct functions related to its intracellular location. Thus, at the Golgi, Rab34 regulates cisternae integrity as well as adiponectin trafficking and oligomerization. At the lipid droplets, this GTPase controls lipid accumulation and lipolysis through its interaction with the E1-ubiquitin ligase, UBA1, which induces the ubiquitination and proteasomal degradation of the fatty acid transporter and member of Rab34 interactome, FABP5. Finally, Rab34 levels in the adipose tissue and adipocytes are regulated in response to obesity and related pathogenic insults (i.e., fibrosis).
CONCLUSIONS: Rab34 plays relevant roles during adipocyte differentiation, including from the regulation of the oligomerization (i.e., biological activity) and secretion of a major adipokine with insulin-sensitizing actions, adiponectin, to lipid storage and mobilization from lipid droplets. Rab34 dysregulation in obesity may contribute to the altered adipokine secretion and lipid metabolism that characterize adipocyte dysfunction in conditions of excess adiposity.
Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
Participants will undergo functional task training using the MyoTrain AR system, which includes the HoloLens 2 augmented reality head-mounted display, four HTC VIVE SteamVR kinematic trackers, eight surface EMG electrodes based on the Element hardware platform, and a desktop computer. Participants will be prompted to use a pattern recognition-based myoelectric controller to operate a virtual prosthesis and complete a simulation of the GaMA Cup Transfer Task.
The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
PLWCHB on stable nucleos(t)ide analog (NA) therapy will be randomized 3:1 to receive repeat dose of either GSK3965193 (Dose E) or placebo. This part will commence after completion of both Part 1 and Part 2.
Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
Most mycoplasma species are the extracellular parasites affecting different cellular processes including proliferation, cell cycle, protein synthesis, DNA repair and others. Mycoplasma infection was shown to contribute to the pathology of various diseases, including cancer. Upon infection, mycoplasmas typically activate the tumor-associated NF-kB pathway, which is associated with EMT, the main mechanism of metastasis. In this study, we found that two different mycoplasma strains, M. arginini and M. salivarium, promoted the initiation of EMT and simultaneous suppression of the p53 tumor suppressor in A549 lung cancer cells. This led to an increase of cancer cell motility, resistance to the antitumor drug etoposide concomitantly with decreased autophagy. These data indicate that mycoplasmas are able to increase the tumorigenic potential of cancer host cells.
Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have a CBC and a chemistry profile checked periodically. If abnormal liver tests or renal tests persist or worsen, CELEBREX should be discontinued.

In controlled clinical trials, elevated BUN occurred more frequently in patients receiving CELEBREX compared with patients on placebo. This laboratory abnormality was also seen in patients who received comparator NSAIDs in these studies. The clinical significance of this abnormality has not been established.
PURPOSE: QT interval prolongation is one of the most common electrocardiographic (ECG) abnormalities in patients with aneurysmal subarachnoid hemorrhage (aSAH). Whether corrected QT interval (QTc) prolongation is associated with perioperative cardiac events and dismal neurological outcome in mid to long-term follow-up in patients after aSAH is insufficiently studied and remains controversial.
METHODS: We retrospectively studied the adult (≥ 18 years) patients admitted to our institution between Jan 2018 and Dec 2020 for aSAH who underwent intracranial aneurysm clipping or embolization. The patients were divided into 2 groups (normal and QTc prolongation groups) according to their QTc. To minimize the confounding bias, a propensity score matching (PSM) analysis was performed to compare the neurologic outcomes between patients with normal QTc and QTc prolongation.
RESULTS: After screening, 908 patients were finally included. The patients were divided into 2 groups: normal QTc groups (n = 714) and long QTc group (n = 194). Female sex, hypokalemia, posterior circulation aneurysm, and higher Hunt-Hess grade were associated with QTc prolongation. In multiple regression analysis, older age, higher hemoglobin level, posterior circulation aneurysm, and higher Hunt-Hess grade were identified to be associated with worse outcome during 1-year follow-up. Before PSM, patients with QTc prolongation had higher rate of perioperative cardiac arrest or ventricular arrhythmias. After PSM, there was no statistical difference between normal and QTc prolongation groups in perioperative cardiac events. However, patients in the QTc prolongation group still had worse neurologic outcome during 1-year follow-up.
CONCLUSIONS: QTc prolongation is associated with worse outcome in patients following SAH, which is independent of perioperative cardiac events.
The search for alternative therapies to antimicrobial growth promoters (AGP) in poultry production has gained momentum in the past years because of consumer preference and government restrictions on the use of AGP in animal production. Flavonoids are plant-derived metabolites that have been studied for their health-promoting properties that could potentially be used as an alternative to AGP in poultry. In a previous study, we showed that the inclusion of a flavonoid-rich corn cultivar (PennHFD1) in the diet improved the health of broilers undergoing necrotic enteritis. However, the mechanisms of action by which the PennHFD1-based diet ameliorated necrotic enteritis are unknown. This study describes the microbial diversity and composition of the jejunum and ileum of chickens co-infected with Eimeria maxima and Clostridium perfringens and treated with a high-flavonoid corn-based diet. Luminal content and mucosal samples from the jejunum and ileum were collected for DNA extraction, 16S rRNA amplicon sequencing and data analyses. The infection model and the dietary treatments significantly changed the alfa diversity indices (Mucosal samples: ASVs, P = 0.04; Luminal content samples: ASVs, P = 0.03), and beta diversities (Mucosal samples: P < 0.01, Luminal content: P < 0.01) of the ileal samples but not those of the jejunal samples. The microbial composition revealed that birds fed the high-flavonoid corn diet had a lower relative abundance of C. perfringens compared to birds fed the commercial corn diet. The treatments also changed the relative abundance of other bacteria that are related to gut health, such as Lactobacillus. We concluded that both the infection model and the dietary high-flavonoid corn changed the broilers' gut microbial diversity and composition. In addition, the decrease in the relative abundance of C. perfringens corroborates with a decrease in mortality and intestinal lesions due to necrotic enteritis. Collecting different segments and sample types provided a broader understanding of the changes in the gut microbiota among treatments.
Delirium is a common postoperative complication occurring in up to 73% of patients sometime during their hospital stay. Elderly patients undergoing major surgical procedures are at highest risk. While many risk factors for delirium are known, the specific pathophysiology of postoperative delirium remains unclear and is likely multifactorial. The most common inciting agents and events include metabolic causes, medications, blood loss, hypoxemia and pain. Pain and its management are intimately related to the likelihood of developing postoperative delirium. As a class, gabapentinoids, such as pregabalin, have proven to reduce postoperative pain and narcotic consumption and therefore may have a role to play in the prevention of postoperative delirium.
A fixed dose of Camrelizumab 200mg will be administered intravenously (without preventive medication), and each infusion lasts 45min (no less than 30min, no more than 60min), once every two weeks; During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle. The treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurred.
Budesonide, the active ingredient of BUDESONIDE Capsules, is a synthetic corticosteroid. Budesonide is designated chemically as 16α, 17-[(1RS)-butylidenebis(oxy)]-11β,21-dihydroxypregna-1,4,diene-3,20-dione. Budesonide is provided as a mixtureof two epimers (22R and 22S). The empirical formula of budesonide is C25H34O6 and its molecular weight is 430.5. Its structural formula is:

Epimer 22 R or Epimer B

Epimer 22 S or Epimer A

Budesonide is a white or almost white, odorless crystalline powder that is practically insoluble in water, freely soluble in dichloromethane, sparingly soluble in alcohol. Its partition coefficient between octanol and water at pH 5 is 1.6 x 103 ionic strength 0.01.

Each capsule for oral administration contains 3 mg of micronized budesonide with the following inactive ingredients: ethylcellulose, acetyltributyl citrate, lactose monohydrate, methacrylic acid copolymer dispersion, triethyl citrate, sodium hydroxide, talc and sugar spheres. The capsule shells have the following inactive ingredients, gelatin, iron oxide red, iron oxide black, iron oxide yellow and titanium dioxide. Sugar Spheres contains the following inactive ingredients Sucrose and corn starch. The imprinting ink contains the following nonvolatile components black iron oxide, potassium hydroxide and shellac.
The invention provides a methicillin-resistant staphylococcus aureus bacteriophage, a composition and application thereof, and belongs to the technical field of bacteriophages. The bacteriophage of methicillin-resistant staphylococcus aureus provided by the invention is bacteriophage MX-6 (with the preservation number of CCTCCNO. M2023029) or bacteriophage ML-1337 (with the preservation number of CCTCCNO. M2023028). The methicillin-resistant staphylococcus aureus phage obtained by separation of the invention has the advantages of wide cleavage spectrum, strong adaptability, no drug resistance gene and toxicity gene, safe animal experiment and no toxic or side effect, and has a certain treatment effect on MRSA infected animals. The bacteriophage and the antibacterial agent are combined for use, so that the bacteriophage and the antibacterial agent have combined synergistic sterilization and/or bacteriostasis capability, can have obvious sterilization and/or bacteriostasis effects on multi-drug resistant MRSA, can reduce the minimum bacteriostasis concentration of the antibacterial agent, and can reduce the use amount of the antibacterial agent.
Auditory nerve (AN) fibers that innervate inner hair cells in the cochlea degenerate with advancing age. It has been proposed that age-related reductions in brainstem frequency-following responses (FFR) to the carrier of low-frequency, high-intensity pure tones may partially reflect this neural loss in the cochlea (Märcher-Rørsted et al., 2022). If the loss of AN fibers is the primary factor contributing to age-related changes in the brainstem FFR, then the FFR could serve as an indicator of cochlear neural degeneration. In this study, we employed electrocochleography (ECochG) to investigate the effects of age on frequency-following neurophonic potentials, i.e., neural responses phase-locked to the carrier frequency of the tone stimulus. We compared these findings to the brainstem-generated FFRs obtained simultaneously using the same stimulation. We conducted recordings in young and older individuals with normal hearing. Responses to pure tones (250 ms, 516 and 1086 Hz, 85 dB SPL) and clicks were recorded using both ECochG at the tympanic membrane and traditional scalp electroencephalographic (EEG) recordings of the FFR. Distortion product otoacoustic emissions (DPOAE) were also collected. In the ECochG recordings, sustained AN neurophonic (ANN) responses to tonal stimulation, as well as the click-evoked compound action potential (CAP) of the AN, were significantly reduced in the older listeners compared to young controls, despite normal audiometric thresholds. In the EEG recordings, brainstem FFRs to the same tone stimulation were also diminished in the older participants. Unlike the reduced AN CAP response, the transient-evoked wave-V remained unaffected. These findings could indicate that a decreased number of AN fibers contributes to the response in the older participants. The results suggest that the scalp-recorded FFR, as opposed to the clinical standard wave-V of the auditory brainstem response, may serve as a more reliable indicator of age-related cochlear neural degeneration.
During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
The proposed TECTRAM solution integrates standalone electronic device with the existing-IoT based applications, and renders almost every object traceable and practically implementable due to its simplified and cost-effective design. The disclosed system includes a standalone electronic device(s), and a communication device for device-2-device interaction. The standalone unit is based on Technology Enabled Enhanced Contact Tracing Mechanism (TECTRAM). The TECTRAM unit (dev1) is configured to communicate with the one or more neighbouring contact tracing units and to store the unique identifier and status of the neighbouring contact tracing units. The present invention renders the technical effect of effectively having far reaching impact on contact tracing, and brings the non-smartphone users, who currently are completely devoid of the tracing facility, under the monitoring range, remarkably without breaching their privacy. This is essential in the event of pandemic to control the breakout.